APA (7th ed.) Citation

Mei, J., Jiang, G., Chen, Y., Xu, Y., Wan, Y., Chen, R., . . . Xu, J. (2022, July). HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. BMC Cancer.

Chicago Style (17th ed.) Citation

Mei, Jie, et al. "HLA Class II Molecule HLA-DRA Identifies Immuno-hot Tumors and Predicts the Therapeutic Response to Anti-PD-1 Immunotherapy in NSCLC." BMC Cancer Jul. 2022.

MLA (9th ed.) Citation

Mei, Jie, et al. "HLA Class II Molecule HLA-DRA Identifies Immuno-hot Tumors and Predicts the Therapeutic Response to Anti-PD-1 Immunotherapy in NSCLC." BMC Cancer, Jul. 2022.